These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 30827507)
1. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway. Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736 [TBL] [Abstract][Full Text] [Related]
3. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Yan X; Fraser M; Qiu Q; Tsang BK Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells. Puca R; Nardinocchi L; Pistritto G; D'Orazi G Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248 [TBL] [Abstract][Full Text] [Related]
5. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response. Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534 [TBL] [Abstract][Full Text] [Related]
6. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213 [TBL] [Abstract][Full Text] [Related]
7. Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Muscolini M; Cianfrocca R; Sajeva A; Mozzetti S; Ferrandina G; Costanzo A; Tuosto L Mol Cancer Ther; 2008 Jun; 7(6):1410-9. PubMed ID: 18566213 [TBL] [Abstract][Full Text] [Related]
8. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707 [TBL] [Abstract][Full Text] [Related]
9. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Sasaki H; Sheng Y; Kotsuji F; Tsang BK Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757 [TBL] [Abstract][Full Text] [Related]
10. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity. Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908 [TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Zhang C; Wang M; Shi C; Shi F; Pei C Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351 [TBL] [Abstract][Full Text] [Related]
12. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M; Bai T; Tsang BK Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180 [TBL] [Abstract][Full Text] [Related]
13. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398 [TBL] [Abstract][Full Text] [Related]
14. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells. Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135 [TBL] [Abstract][Full Text] [Related]
15. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254 [TBL] [Abstract][Full Text] [Related]
16. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Zhang X; Qi Z; Yin H; Yang G Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer. Zou W; Ma X; Yang H; Hua W; Chen B; Cai G Exp Biol Med (Maywood); 2017 Mar; 242(5):497-504. PubMed ID: 28056551 [TBL] [Abstract][Full Text] [Related]
18. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2. Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785 [TBL] [Abstract][Full Text] [Related]
19. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900 [TBL] [Abstract][Full Text] [Related]
20. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]